IRhythm plans Zio MCT FDA filing in 2027 while raising 2026 revenue outlook to $890M-$895M

• "Third quarter revenue was $221.6 million, up nearly 15% year-over-year" (President, CEO & Director Quentin Blackford), while noting "our core Zio Monitor business again outperforming our expectations" (President Blackford) and that "Zio AT" revenue was "roughly flat compared to the prior year" (President Blackford).

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.